Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Breast cancer subtype and survival among Indigenous American women in Peru.
Tamayo LI, Vidaurre T, Navarro Vásquez J, Casavilca S, Aramburu Palomino JI, Calderon M, Abugattas JE, Gomez HL, Castaneda CA, Song S, Cherry D, Rauscher GH, Fejerman L. Tamayo LI, et al. Among authors: vidaurre t. PLoS One. 2018 Sep 5;13(9):e0201287. doi: 10.1371/journal.pone.0201287. eCollection 2018. PLoS One. 2018. PMID: 30183706 Free PMC article.
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L. Hess KR, et al. Among authors: vidaurre t. J Clin Oncol. 2006 Sep 10;24(26):4236-44. doi: 10.1200/JCO.2006.05.6861. Epub 2006 Aug 8. J Clin Oncol. 2006. PMID: 16896004
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve SS, Sledge GW. Carlson RW, et al. Among authors: vidaurre t. Breast Cancer Res Treat. 2012 Jun;133(3):1049-56. doi: 10.1007/s10549-012-1997-5. Epub 2012 Mar 15. Breast Cancer Res Treat. 2012. PMID: 22418699 Free PMC article. Clinical Trial.
Cost-effectiveness analysis of breast cancer control interventions in Peru.
Zelle SG, Vidaurre T, Abugattas JE, Manrique JE, Sarria G, Jeronimo J, Seinfeld JN, Lauer JA, Sepulveda CR, Venegas D, Baltussen R. Zelle SG, et al. Among authors: vidaurre t. PLoS One. 2013 Dec 10;8(12):e82575. doi: 10.1371/journal.pone.0082575. eCollection 2013. PLoS One. 2013. PMID: 24349314 Free PMC article.
PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HL. Castaneda CA, et al. Among authors: vidaurre t. Hematol Oncol Stem Cell Ther. 2014 Dec;7(4):142-8. doi: 10.1016/j.hemonc.2014.09.007. Epub 2014 Oct 29. Hematol Oncol Stem Cell Ther. 2014. PMID: 25467032 Free article.
Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy.
Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C, Dolores-Cerna K, Belmar-Lopez C, Abugattas J, Calderon G, De La Cruz M, Cotrina M, Dunstan J, Gomez HL, Vidaurre T. Castaneda CA, et al. Among authors: vidaurre t. World J Clin Oncol. 2016 Oct 10;7(5):387-394. doi: 10.5306/wjco.v7.i5.387. World J Clin Oncol. 2016. PMID: 27777881 Free PMC article.
[Accelerating cancer control innovations in Peru].
Santos-Ortiz C, Manrique J, Amorín E, Sarria G, Salazar M, Limache A, Villena M, Dunstan J, Abugattas J, Vidaurre T. Santos-Ortiz C, et al. Among authors: vidaurre t. Rev Peru Med Exp Salud Publica. 2016 Jul-Sep;33(3):535-539. doi: 10.17843/rpmesp.2016.333.2318. Rev Peru Med Exp Salud Publica. 2016. PMID: 27831618 Free article. Spanish.
43 results